Literature DB >> 6707342

"Maximal" drug therapy is not necessarily optimal in chronic angina pectoris.

M Tolins, E K Weir, E Chesler, G L Pierpont.   

Abstract

Beta-adrenergic blocking agents, nitrates and calcium channel antagonists are effective in treating angina pectoris, but much remains unknown about how they act in combination. Consequently, treadmill exercise was used to assess the relative efficacy of nifedipine or isosorbide dinitrate, or both, in 19 patients with stable angina receiving propranolol. Propranolol therapy was continued and either placebo, nifedipine (20 mg), isosorbide dinitrate (20 mg) or both drugs were given randomly 1 1/2 hours before exercise in a double-blind trial. In 16 patients who completed the protocol, heart rate at rest during propranolol therapy was 53.7 +/- 1.9 beats/min (mean +/- standard error of the mean); it increased 4.6 +/- 1.2 beats/min with the addition of nifedipine (p less than 0.01), but was unchanged with isosorbide dinitrate or both combined. Compared with values during treatment with propranolol alone, systolic blood pressure at rest decreased with each vasodilator individually and when combined. Rate-pressure product at maximal exercise was the same with all combinations. Exercise duration was 467 +/- 50 seconds with propranolol, increased to 556 +/- 47 seconds with isosorbide dinitrate (p less than 0.05) and to 636 +/- 50 seconds with nifedipine (p less than 0.001). Exercise duration with all three drugs was 597 +/- 47 seconds (p less than 0.01 compared with propranolol alone). The improvement with nifedipine was greater than with isosorbide dinitrate (p less than 0.05) but exercise duration was not significantly different with the combination of these drugs than when either drug was used alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6707342     DOI: 10.1016/s0735-1097(84)80366-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Need for invasive cardiological assessment and intervention: a ten year review.

Authors:  C A MacRae; M S Marber; C Keywood; M Joy
Journal:  Br Heart J       Date:  1992-02

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  The need for invasive cardiological assessment and operation: viewpoint of a district general hospital.

Authors:  T Cripps; M S Dennis; M Joy
Journal:  Br Heart J       Date:  1986-05

Review 4.  [Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy].

Authors:  M Leschke; F C Schoebel; T W Jax; C M Schannwell; R Marx; B E Strauer
Journal:  Herz       Date:  1997-10       Impact factor: 1.443

Review 5.  Combination and triple therapy in patients with stable angina pectoris not adequately controlled by optimal β-blocker therapy.

Authors:  W E M Kok; F C Visser; C A Visser
Journal:  Neth Heart J       Date:  2002-11       Impact factor: 2.380

6.  Selection of optimal therapy for chronic stable angina.

Authors:  Udho Thadani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-02

Review 7.  Combination of nitrates with other antianginal drugs.

Authors:  K E Andersson; P Hoglund
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  Abrupt withdrawal of isosorbide 5-mononitrate (Imdur) after long term treatment in stable angina pectoris. A preliminary report.

Authors:  N Rehnqvist; G Olsson; J Engvall; U Rosenqvist; G Nyberg; A Aberg; G Ulvenstam; A Uusitalo; O Keyriläinen; R Härkönen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 9.  The combination of antianginal drugs: effects and indications.

Authors:  P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

Review 10.  Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.